Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study

Table 4 Relative survival for 188 male and 290 female patients with AGel amyloidosis in the FIN-GAR phase II registry and a previous study on survival [27]

Age group	n in the beginning	Observed survival	Expected survival	Cumulative relative survival
Male
30–34	188	0.9893	0.9777	1.0119
35–39	185	0.9893	0.9577	1.0330
40–44	183	0.9839	0.9360	1.0511
45–49	180	0.9674	0.9065	1.0671
50–54	174	0.9448	0.8669	1.0899
55–59	165	0.8800	0.8136	1.0817
60–64	145	0.8172	0.7415	1.1021
65–69	125	0.7073	0.6468	1.0936
70–74	97	0.5085	0.5300	0.9594
75–79	62	0.3221	0.3927	0.8200
80–84	36	0.0552	0.2550	0.2165
85–89	5	0.0000	0.1274	0.0000
Female
30–34	290	1.0000	0.9907	1.0094
35–39	287	0.9965	0.9820	1.0147
40–44	284	0.9965	0.9728	1.0244
45–49	280	0.9929	0.9610	1.0332
50–54	267	0.9813	0.9448	1.0387
55–59	246	0.9688	0.9220	1.0507
60–64	222	0.9459	0.8883	1.0648
65–69	195	0.8370	0.8386	0.9982
70–74	149	0.7339	0.7641	0.9605
75–79	110	0.4703	0.6494	0.7241
80–84	59	0.1513	0.4863	0.3112
85–89	17	0.0504	0.2809	0.1796
90–94	5	0.0101	0.0994	0.1015
95–99	1	0.0000	0.0182	0.0000

ISSN: 1750-1172